U.S. Markets close in 2 hrs 19 mins

Rigel Pharmaceuticals, Inc. (RIGL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.415-0.01 (-0.21%)
As of 1:40PM EDT. Market open.
People also watch

Rigel Pharmaceuticals, Inc.

1180 Veterans Boulevard
South San Francisco, CA 94080
United States

IndustryDrugs - Generic
Full Time Employees77

Key Executives

Mr. Raul R. RodriguezChief Exec. Officer, Pres and Director862.37kN/A56
Mr. Ryan D. MaynardChief Financial Officer and Exec. VP603.5kN/A48
Ms. Dolly A. VanceExec. VP of Corp. Affairs, Gen. Counsel and Corp. Sec.650.8kN/A52
Dr. Anne-Marie S. Duliege M.D., M.S.Chief Medical Officer and Exec. VP541.2kN/A58
Mr. Eldon C. Mayer IIIChief Commercial Officer and Exec. VP175.92kN/A56
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company’s clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It is also developing two oncology product candidates, which are in Phase I and Phase II. Rigel Pharmaceuticals, Inc. has license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of an oncology program; and Daiichi Sankyo to pursue research related to ligases. The company was founded in 1996 and is based in South San Francisco, California.

Corporate Governance

Rigel Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 5. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.